Skip to main content

Table 3 HRs and 95% CIs of incident eGFR decline ≥ 40% according to tertiles of FPG variability measures in Tehran Lipid and Glucose Study

From: The association between fasting plasma glucose variability and incident eGFR decline: evidence from two cohort studies

Variability measures

Model 1

Model 2

Model 3

Model 4

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

With diabetes

SD

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.20 (0.69–2.10)

1.06 (0.59–1.90)

0.93 (0.53–1.66)

0.88 (0.49–1.58)

 T3

0.98 (0.54–1.77)

0.76 (0.39–1.47)

0.77 (0.42–1.44)

0.67 (0.33–1.33)

 P trend

0.968

0.414

0.417

0.254

CV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.04 (0.60–1.82)

0.96 (0.53–1.73)

0.80 (0.44–1.43)

0.77 (0.42–1.39)

 T3

0.94 (0.53–1.66)

0.74 (0.40–1.37)

0.74 (0.41–0.34)

0.70 (0.38–1.29)

 P trend

0.828

0.332

0.327

0.253

ARV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.47 (0.84–2.58)

1.29 (0.71–2.33)

0.99 (0.55–1.79)

0.94 (0.52–1.72)

 T3

1.09 (0.60–2.01)

0.84 (0.43–1.65)

0.83 (0.44–1.55)

0.71 (0.35–1.44)

 P trend

0.749

0.588

0.539

0.344

VIM

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.10 (0.63–1.92)

1.18 (0.67–2.09)

1.09 (0.62–1.92)

1.10 (0.62–1.93)

 T3

0.94 (0.53–1.66)

0.84 (0.46–1.51)

0.82 (0.46–1.47)

0.83 (0.46–1.49)

 P trend

0.835

0.577

0.512

0.746

Without diabetes

SD

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.28 (0.80–2.07)

1.37 (0.84–2.21)

1.32 (0.81–2.13)

1.31 (0.81–2.12)

 T3

1.61 (1.02–2.53)

1.67 (1.05–2.64)

1.61 (1.02–2.55)

1.60 (1.01–2.54)

 P trend

0.039

0.029

0.041

0.047

CV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.36 (0.85–2.18)

1.43 (0.89–2.30)

1.43 (0.90–2.31)

1.44 (0.89–2.30)

 T3

1.53 (0.97–2.42)

1.56 (0.98–2.48)

1.55 (0.98–2.47)

1.55 (0.97–2.46)

 P trend

0.071

0.064

0.065

0.068

ARV

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.08 (0.68–1.70)

1.18 (0.74–1.88)

1.21 (0.76–1.93)

1.21 (0.76–1.92)

 T3

1.27 (0.82–1.96)

1.38 (0.89–2.15)

1.30 (0.84–2.01)

1.28 (0.82–1.99)

 P trend

0.286

0.147

0.242

0.272

VIM

 T1

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 T2

1.42 (0.88–2.28)

1.49 (0.93–2.41)

1.49 (0.93- 2.39)

1.49 (0.92–2.40)

 T3

1.65 (1.04–2.62)

1.66 (1.04–2.67)

1.69 (1.06–2.69)

1.69(1.06–2.69)

 P trend

0.034

0.035

0.029

0.029

  1. Model 1: adjusted for age and sex at baseline (phase 2)
  2. Model 2: Model 1 + marital status, education, ever smoking, prevalent CVD, physical activity, anti-diabetic drug use, anti-hypertensive drug, lipid-lowering drug, BMI, WC, SBP, DBP, eGFR, and FPG at baseline (phase 2)
  3. Model 3: Model 1 + marital status, education, ever smoking, prevalent CVD, and physical activity at baseline (phase 2), and anti-diabetic drug use, anti-hypertensive drug, and lipid-lowering drug over phases 2–4, and average BMI, WC, SBP, DBP, and eGFR over phases 2–4
  4. Model 4: Model 3 + average FPG